MGNX MacroGenics Inc.

-0.13  -1%
Previous Close 11.53
Open 11.5
Price To Book 1.7
Market Cap 481753512
Shares 42,259,080
Volume 663,797
Short Ratio
Av. Daily Volume 465,305

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data released at ASH December 2018. ORR 26%; CR 19%.
Phase 3 PFS data due 1Q 2019.
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 2 updated data presented at ASCO GI January 17, 2019. ORR 33%, median PFS 4.1 months.
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 1 data at SITC November 2018.
Solid tumors
Phase 1 trial placed on partial clinical hold December 7, 2018.
Solid tumors

Latest News

  1. What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
  2. Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
  3. 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
  4. Medical Products Industry Gathering Steam: 3 Stocks to Buy
  5. At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
  6. MacroGenics to Present at the 37th Annual J.P. Morgan Healthcare Conference
  7. Are MacroGenics, Inc.’s (NASDAQ:MGNX) Interest Costs Too High?
  8. 5 Beaten-Down Medical Product Stocks to Rebound in 2019
  9. MacroGenics Inc (MGNX): Hedge Funds Are Snapping Up
  10. Why MacroGenics Stock Is Getting Hammered Today
  11. MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
  12. Edited Transcript of MGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT
  13. Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
  14. New Research: Key Drivers of Growth for Conagra Brands, MacroGenics, Transocean, Harris, Analog Devices, and DryShips — Factors of Influence, Major Initiatives and Sustained Production
  15. What's in Store for GW Pharma (GWPH) This Earnings Season?
  16. MacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART® Program at the EORTC-NCI-AACR Symposium in Dublin
  17. How Has Cara Therapeutics’ 2018 Performance Shaken Out?